Markers in the blood can predict how multiple sclerosis will develop and what drugs will be ­effective, a study found.

Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

Bucks County resident Joseph “Smiley” Terinoni was recently presented with a citation from the Pennsylvania House of ...

ECTRIMS 2024 Investor Science Call September 20, 2024 10:00 AM ETCompany ParticipantsThomas Kudsk - IRJiwon Oh - MD, PhD, St.

Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and ...

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...

The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...

Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed ...

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...

Vitamin D is linked to a 34% reduction in the relative risk for disease activity in patients with clinically isolated ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...